. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, offers communication strategies for staying confident in genuine pharmaceuticals while also remaining vigilant against counterfeit threats.

Balancing Awareness and Assurance

Articles

The acquisition merges eBlu’s automation platform with Knipper’s nationwide distribution network, streamlining benefit verification, prior authorization, and patient onboarding while reducing administrative burdens for specialty providers.

Knipper Health Purchases eBlu Solutions to Accelerate Therapy Initiation

In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving

How Competition, Access, and Reimbursement Will Shape the Next Wave of Innovation

In the fourth part of this roundtable discussion, a panel of subject matter experts dive into data exchange challenges relating to the Drug Supply Chain Security Act.

Peer Exchange: How DSCSA Is Transforming Supply Chain Data Exchange (Episode 4)

The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.

Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines. 

The Hidden Challenge of Reporting Counterfeit Medicines

Pharma Pulse 7/18/25: How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies; Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

The Biosimilar Void

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined. 

Trump Says Pharma Industry Should Expect Tariffs by Aug. 1

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely legitimize online medicine procurement.

News